$409.01 Million in Sales Expected for Qiagen NV (QGEN) This Quarter

Share on StockTwits

Wall Street brokerages expect Qiagen NV (NASDAQ:QGEN) to report $409.01 million in sales for the current quarter, according to Zacks. Three analysts have issued estimates for Qiagen’s earnings. The lowest sales estimate is $406.20 million and the highest is $413.41 million. Qiagen posted sales of $396.86 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 3.1%. The business is expected to report its next earnings results on Wednesday, January 30th.

On average, analysts expect that Qiagen will report full year sales of $1.51 billion for the current fiscal year. For the next year, analysts anticipate that the firm will post sales of $1.61 billion, with estimates ranging from $1.56 billion to $1.66 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that follow Qiagen.

Qiagen (NASDAQ:QGEN) last posted its quarterly earnings data on Monday, October 29th. The company reported $0.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.33 by $0.02. The business had revenue of $377.90 million during the quarter, compared to analysts’ expectations of $380.11 million. The business’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same period in the previous year, the business posted $0.32 EPS.

A number of equities analysts recently issued reports on QGEN shares. Deutsche Bank reissued a “buy” rating on shares of Qiagen in a report on Friday, August 3rd. Commerzbank reaffirmed a “buy” rating on shares of Qiagen in a report on Wednesday, August 29th. Barclays reaffirmed a “buy” rating and set a $43.00 price target on shares of Qiagen in a report on Thursday, September 6th. Finally, BidaskClub raised shares of Qiagen from a “sell” rating to a “hold” rating in a report on Wednesday, August 29th. Eight investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $39.13.

A number of large investors have recently modified their holdings of the business. Massachusetts Financial Services Co. MA lifted its holdings in shares of Qiagen by 3.3% in the third quarter. Massachusetts Financial Services Co. MA now owns 12,133,579 shares of the company’s stock worth $459,619,000 after buying an additional 387,090 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Qiagen by 1.6% in the third quarter. BlackRock Inc. now owns 6,271,114 shares of the company’s stock worth $237,550,000 after buying an additional 96,578 shares in the last quarter. FIL Ltd lifted its holdings in shares of Qiagen by 92.4% in the third quarter. FIL Ltd now owns 4,405,352 shares of the company’s stock worth $166,744,000 after buying an additional 2,116,254 shares in the last quarter. Hardman Johnston Global Advisors LLC lifted its holdings in shares of Qiagen by 11.1% in the third quarter. Hardman Johnston Global Advisors LLC now owns 4,177,260 shares of the company’s stock worth $158,235,000 after buying an additional 418,921 shares in the last quarter. Finally, First Trust Advisors LP lifted its holdings in shares of Qiagen by 56.7% in the third quarter. First Trust Advisors LP now owns 2,677,633 shares of the company’s stock worth $101,429,000 after buying an additional 969,188 shares in the last quarter. 62.23% of the stock is currently owned by institutional investors and hedge funds.

Shares of QGEN traded down $0.48 on Monday, reaching $35.97. The company’s stock had a trading volume of 599,414 shares, compared to its average volume of 1,007,009. Qiagen has a 12-month low of $30.44 and a 12-month high of $39.45.

Qiagen Company Profile

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Featured Article: How can you know how many shares are floating?

Get a free copy of the Zacks research report on Qiagen (QGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Qiagen (NASDAQ:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.